Incidence, implications, and management of sense-B-noise failure in subcutaneous cardioverter-defibrillator patients: insights from a large multicentre registry
- PMID: 38861398
- PMCID: PMC11212320
- DOI: 10.1093/europace/euae161
Incidence, implications, and management of sense-B-noise failure in subcutaneous cardioverter-defibrillator patients: insights from a large multicentre registry
Abstract
Aims: Subcutaneous implantable cardioverter-defibrillators (S-ICDs) offer potentially distinct advantages over transvenous defibrillator systems. Recent randomized trials showed significantly lower lead failure rates than transvenous ICD. Still, S-ICDs remain associated with the risk of inappropriate shocks (IAS). While previous studies have reported varying causes of IAS, this study explores a rare cause of IAS, referred to as 'sense-B-noise.' It was recently described in case series, but its incidence has not been studied in a large cohort of S-ICD patients.
Methods and results: We retrospectively reviewed data from patients implanted with S-ICD models 1010, A209, and A219 between October 2009 and July 2023 across nine centres in Europe and the USA. The analysis concentrated on determining the incidence and understanding the implications of sense-B-noise events. Sense-B-noise represents a rare manifestation of distinct electrogram abnormalities within the primary and alternate sensing vectors. Data were collected from medical records, device telemetry, and manufacturer reports for investigation. This registry is registered on clinicaltrials.gov (NCT05713708). Subcutaneous implantable cardioverter-defibrillator devices of the 1158 patients were analysed. The median follow-up time for all patients was 46 (IQR 23-64) months. In 107 patients (9.2%) ≥1 IAS was observed during follow-up. Sense-B-noise failure was diagnosed in six (0.5 and 5.6% of all IAS) patients, in all patients, the diagnosis was made after an IAS episode. Median lead dwell time in the affected patients was 23 (2-70) months. To resolve the sense-B-noise defect, in three patients reprogramming to the secondary vector was undertaken, and two patients underwent system removal with subsequent S-ICD reimplantation due to low amplitude in the secondary vector. In one patient, the secondary vector was initially programmed, and subsequently, an S-ICD system exchange was performed due to T-wave-oversensing IAS episodes.
Conclusion: This multicentre analysis' findings shed light on a rare but clinically highly significant adverse event in S-ICD therapy. To our knowledge, we provide the first systematic multicentre analysis investigating the incidence of sense-B-noise. Due to being difficult to diagnose and limited options for resolution, management of sense-B-noise is challenging. Complete system exchange may be the only option for some patients. Educating healthcare providers involved in S-ICD patient care is crucial for ensuring accurate diagnosis and effective management of sense-B-noise issues.
Keywords: Device malfunction; Inappropriate shocks; Multicentre registry; Sense-B-noise; Subcutaneous implantable cardioverter-defibrillator (S-ICD).
© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.
Conflict of interest statement
Conflict of interest: J.W. reports having received lecture fees from Abbott and Boston Scientific and educational fees from Boston Scientific and Johnson&Johnson. J.L. and D.S. report having received lecture fees from Johnson&Johnson, Abbott, and Boston Scientific. A.S. reports having received lecture fees from Medtronic, Boston Scientific, Abbott, and Johnson&Johnson. J.H. reports having received educational fees from Boston Scientific, Medtronic, Abbott, and Biotronik and speaker fees from Abbott. N.S. reports having received research funding from Abbott. N.B. reports having received an educational grant from Biotronik and speaker fees from Medtronic and Abbott, all outside this submitted work. A.B. reports having received consultant and/or speaker fees from Abbott, Bayer Healthcare, Biosense Webster, Biotronik, Boston Scientific, Bristol-Myers Squibb, Cook Medical, Daiichi Sankyo, Medtronic, Pfizer, and Spectranetics/Philips. J.S. reports having received educational fees from Boston Scientific and Johnson&Johnson and lecture fees from Abbott. All other authors report nothing to declare.
Figures


Similar articles
-
Occurrence of premature battery depletion in a large multicentre registry of subcutaneous cardioverter-defibrillator patients.Europace. 2024 Jul 2;26(7):euae170. doi: 10.1093/europace/euae170. Europace. 2024. PMID: 38885309 Free PMC article.
-
Sense-B-noise: an enigmatic cause for inappropriate shocks in subcutaneous implantable cardioverter defibrillators.Europace. 2023 Feb 16;25(2):767-774. doi: 10.1093/europace/euac202. Europace. 2023. PMID: 36353759 Free PMC article.
-
Oversensing issues leading to device extraction: When subcutaneous implantable cardioverter-defibrillator reached a dead-end.Heart Rhythm. 2020 Jan;17(1):66-74. doi: 10.1016/j.hrthm.2019.07.004. Epub 2019 Jul 8. Heart Rhythm. 2020. PMID: 31295585
-
Electromagnetic interference from left ventricular assist devices in patients with subcutaneous implantable cardioverter-defibrillators.J Cardiovasc Electrophysiol. 2020 May;31(5):1195-1201. doi: 10.1111/jce.14431. Epub 2020 Mar 9. J Cardiovasc Electrophysiol. 2020. PMID: 32128931 Review.
-
Subcutaneous Versus Transvenous Implantable Defibrillator Therapy: A Meta-Analysis of Case-Control Studies.JACC Clin Electrophysiol. 2017 Dec 26;3(13):1475-1483. doi: 10.1016/j.jacep.2017.07.017. Epub 2017 Sep 27. JACC Clin Electrophysiol. 2017. PMID: 29759827
References
-
- Knops RE, Olde Nordkamp LRA, Delnoy P-PHM, Boersma LVA, Kuschyk J, El-Chami MFet al. . Subcutaneous or transvenous defibrillator therapy. N Engl J Med 2020;383:526–36. - PubMed
-
- Viani S, Migliore F, Ottaviano L, Biffi M, Ammendola E, Ricciardi Get al. . Longevity of model 3501 subcutaneous implantable cardioverter-defibrillator leads in clinical practice. Hear Rhythm 2022;19:1206–7. - PubMed
-
- Gold MR, El-Chami MF, Burke MC, Upadhyay GA, Niebauer MJ, Prutkin JMet al. . Postapproval study of a subcutaneous implantable cardioverter-defibrillator system. J Am Coll Cardiol 2023;82:383–97. - PubMed
Publication types
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Medical